Daptomycin: a comparison of two intravenous formulations

Area of Science:

• Pharmacology
• Infectious Diseases
• Drug Development

Background:

• Daptomycin is a cyclic lipopeptide antibiotic effective against Gram-positive bacteria.
• Approved by the FDA for complicated skin infections and Staphylococcus aureus bacteremia.
• A new formulation, daptomycin RF, was approved in 2016 for the same indications.

Purpose of the Study:

• To discuss the rationale and value of the new daptomycin RF formulation.
• To compare the original daptomycin formulation with daptomycin RF.
• To highlight the improved stability and reconstitution of daptomycin RF.

Main Methods:

• Review of pivotal clinical trials and nonclinical studies.
• Comparison of product characteristics between daptomycin and daptomycin RF.
• Discussion of clinical implications for healthcare professionals.

Main Results:

• Nonclinical studies indicate equivalent efficacy and safety for both daptomycin formulations.
• Daptomycin RF offers enhanced stability and more rapid in-vial reconstitution.
• Daptomycin RF maintains the same broad-spectrum Gram-positive antibacterial coverage.

Conclusions:

• Daptomycin RF provides a valuable alternative with improved handling characteristics.
• The new formulation maintains the established efficacy and safety profile of daptomycin.
• Daptomycin RF supports efficient clinical use for Gram-positive infections.